Abstract:Background: Amoxicillin is an oral semi-synthetic, β-lactam antibiotic used to treat bacterial infections caused by susceptible micro organisms. It is usually prepared in capsule, tablet and powder for oral suspension form. Solid dosage forms for oral administration pose bioavailability problems related to the absorption process The World Health Organization (WHO) has promoted the use of generic brands in order to make the cost of medicines affordable. Generic substitution could be considered when a generic copy of a reference drug contains identical amounts of the same active ingredient in the same dose formulation and route of administration. However, the presences of generic products those are not interchangeable with that of the innovator and/or with each others have been reported. Objectives: To evaluate and compare the in-vitro dissolution profiles of different generic brands of amoxicillin capsules with the innovator that are available in Ethiopian market. Methods: Dissolution profiles for nine brands of amoxicillin capsules contained amoxicillin 500 mg which are available in Ethiopian market were determined using a method from the United States Pharmacopoeia (USP, 2009). The obtained dissolution profile data of the eight brands were evaluated and compared with the innovator brand (Amoxil™) using two different statistical methods: the fit factors (f1 & f2) and the dissolution efficiency (D.E.) model. Most generic brands of amoxicillin capsules (62.5% of the tested brands) are not interchangeable with the innovator brand. Results: The calculated f1 factor for Brand A and Brand G are 10.1 and 1.1 respectively. However, for the rest six brands the f1 factors are greater than 15. The f2 factor for Brand G is 74.1 and for Brand A is 48.5 which is near to 50. Similarly, the f2 factors for the six brands are less than 50 which support the result of the f1 factors for the dissimilarity of these brands with the innovator brand. The mean dissolution efficiencies as well as the 95% confidence intervals are within ±10% only for two brands, Brand F and Brand G. Conclusions: Most generic brands of amoxicillin capsules (62.5%) are not interchangeable with the innovator brand (Amoxil™).

Modeling and comparison of dissolution profiles for different brands of albendazole boluses

Quality of albendazole tablets legally circulating in the pharmaceutical market of Addis Ababa, Ethiopia: physicochemical evaluation

The Determination of Albendazole and Its Main Metabolites Residues in Bovine Skeletal Muscle

Dissolution Behavior in Vitro and Pharmacokinetic Profile of Albendazole Solid Dispersion in Rats

Improved Dissolution of Albendazole from High Drug Loaded Ternary Solid Dispersion: Formulation and Characterization

Enabling a Novel Solvent Method on Albendazole Solid Dispersion to Improve the in Vivo Bioavailability

The Use of Systemically Absorbed Drugs to Explore An In Vitro Bioequivalence Approach For Comparing Non-Systemically Absorbed Active Pharmaceutical Ingredients in Drug Products For Use in Dogs

Studies on Preparation and Dissolution of Albendazole Solid Dispersions

Comparison of in vitro dissolution of Bisoprolol Fumarate tablets of five Brands marketed in Aden, Yemen

Evaluation and comparison of in-vitro dissolution profiles for different brands of amoxicillin capsules

Albendazole Solid Dispersions Prepared Using Peg6000 And Poloxamer188: Formulation, Characterization Andin Vivoevaluation

Enhanced Oral Bioavailability and Anti-Echinococcosis Efficacy of Albendazole Achieved by Optimizing the "spring" and "Parachute"

Simplified Model-Dependent and Model-Independent Approaches for Dissolution Profile Comparison for Oral Products: Regulatory Perspective for Generic Product Development

A comparative study on vildagliptin brand and its generic equivalents using dissolution test as quality control measure tool

Relevance of Liquid-Liquid Phase Separation of Supersaturated Solution in Oral Absorption of Albendazole from Amorphous Solid Dispersions

Enhancing Albendazole Delivery Using Mesoporous Santa Barbara Amorphous‐15: A Box‐Behnken Design Study

Measurement and correlation of solubility data for albendazole in ten pure solvents and two binary solvent systems from 278.15 K to 323.15 K

Comparative dissolution profiling of generic and standard drug under BCS Based Biowaiver conditions

Improving the Solubility, Stability, and Bioavailability of Albendazole through Synthetic Salts

Determination of the Solubility and Thermodynamic Properties of Albendazole in a Binary Solvent of Ethanol and Water

Dissolution profiles of BCS class II drugs generated by the gastrointestinal simulator alpha has an edge over the compendial USP II method